<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04680832</url>
  </required_header>
  <id_info>
    <org_study_id>MEC-2020-0655</org_study_id>
    <nct_id>NCT04680832</nct_id>
  </id_info>
  <brief_title>Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic ILD</brief_title>
  <acronym>ILDnose</acronym>
  <official_title>Exhaled Breath Analysis Using eNose Technology as a Biomarker for Diagnosis and Disease Progression in Fibrotic Interstitial Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ILDnose study a multinational, multicenter, prospective, longitudinal study in&#xD;
      outpatients with pulmonary fibrosis. The aim is to assess the accuracy of eNose technology as&#xD;
      diagnostic tool for diagnosis and differentiation between the most prevalent fibrotic&#xD;
      interstitial lung diseases. The value of eNose as biomarker for disease progression and&#xD;
      response to treatment is also assessed. Besides, validity of several questionnaires for&#xD;
      pulmonary fibrosis is investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be included in the study after signing written informed consent. eNose&#xD;
      measurements will take place before or after a routine outpatient clinic visit at the same&#xD;
      location as the regular visit, ensuring minimal inconvenience for patients. First, patients&#xD;
      will be asked to rinse their mouth thoroughly with water three times. Subsequently, exhaled&#xD;
      breath analysis will be performed in duplicate with a 1-minute interval. An eNose measurement&#xD;
      consists of five tidal breaths, followed by an inspiratory capacity maneuver to total lung&#xD;
      capacity, a five second breath hold, and subsequently a slow expiration (flow &lt;0.4L/s) to&#xD;
      residual volume. The measurements are non-invasive and will cost approximately 5-10 minutes&#xD;
      in total, including explanation and informed consent procedure. There are no risks associated&#xD;
      with this study and the burden for patients is minimal.&#xD;
&#xD;
      After the measurement, patients will complete a short survey about questions relevant for the&#xD;
      data analysis (food intake in the last two hours, smoking history, medication use,&#xD;
      comorbidities, and symptoms of respiratory infection). In addition, patients will complete&#xD;
      the L-PF questionnaire and the Global Rating of Change scale (GRoC). The L-PF questionnaire&#xD;
      consists of 21 questions on a 5-point Likert scale about the impact of pulmonary fibrosis on&#xD;
      quality of life, and takes about 3 minutes to complete. The GRoC consists of one question on&#xD;
      a scale from -7 to 7: were there any changes in your quality of life since your last visit?&#xD;
      Symptoms (cough and dyspnea) will be scored on a 10 cm VAS scale from -5 to 5.&#xD;
&#xD;
      Next to eNose measurements, demographic data and physiological parameters of patients will be&#xD;
      collected from the medical records at baseline, month 6, and month 12. Parameters such as&#xD;
      age, gender, diagnosis, time since diagnosis, comorbidities, medication, pulmonary function&#xD;
      (forced vital capacity (FVC) and diffusion capacity of the lung for carbon monoxide (DLCO)),&#xD;
      laboratory parameters (i.e. auto-immune antibodies), HRCT pattern, BAL results and if&#xD;
      applicable also genetic mutations, will be recorded and stored in an electronic case report&#xD;
      form. These parameters will be collected as part of routine daily care, patients will not&#xD;
      undergo any additional tests for study purposes. HRCT scans will be re-analysed centrally by&#xD;
      an experienced ILD thoracic radiologist. Mortality and lung function parameters will also be&#xD;
      collected at 24 months, if this information is available.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy for IPF - CHP</measure>
    <time_frame>Baseline</time_frame>
    <description>Accuracy for differentiating IPF from CHP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for IPF - CHP</measure>
    <time_frame>Baseline</time_frame>
    <description>AUC for differentiating IPF from CHP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for IPF - iNSIP</measure>
    <time_frame>Baseline</time_frame>
    <description>AUC for differentiating IPF from iNSIP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy for IPF - iNSIP</measure>
    <time_frame>Baseline</time_frame>
    <description>Accuracy for differentiating IPF from iNSIP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for IPF - IPAF</measure>
    <time_frame>Baseline</time_frame>
    <description>AUC for differentiating IPF from IPAF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy for IPF - IPAF</measure>
    <time_frame>Baseline</time_frame>
    <description>Accuracy for differentiating IPF from IPAF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy for IPF - CTD-ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>Accuracy for differentiating IPF from CTD-ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for IPF - CTD-ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>AUC for differentiating IPF from CTD-ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy for IPF - unclassifiable ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>Accuracy for differentiating IPF from unclassifiable ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for IPF - unclassifiable ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>AUC for differentiating IPF from unclassifiable ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy for CHP - iNSIP</measure>
    <time_frame>Baseline</time_frame>
    <description>Accuracy for differentiating CHP from iNSIP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for CHP - iNSIP</measure>
    <time_frame>Baseline</time_frame>
    <description>AUC for differentiating CHP from iNSIP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy for CHP - IPAF</measure>
    <time_frame>Baseline</time_frame>
    <description>Accuracy for differentiating CHP from IPAF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for CHP - IPAF</measure>
    <time_frame>Baseline</time_frame>
    <description>AUC for differentiating CHP from IPAF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy for CHP - CTD-ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>Accuracy for differentiating CHP from CTD-ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for CHP - CTD-ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>AUC for differentiating CHP from CTD-ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy for CHP - unclassifiable ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>Accuracy for differentiating CHP from unclassifiable ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for CHP - unclassifiable ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>AUC for differentiating CHP from unclassifiable ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy for iNSIP - IPAF</measure>
    <time_frame>Baseline</time_frame>
    <description>Accuracy for differentiating iNSIP from IPAF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for iNSIP - IPAF</measure>
    <time_frame>Baseline</time_frame>
    <description>AUC for differentiating iNSIP from IPAF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy for iNSIP - CTD-ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>Accuracy for differentiating iNSIP from CTD-ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for iNSIP - CTD-ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>AUC for differentiating iNSIP from CTD-ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy for iNSIP - unclassifiable ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>Accuracy for differentiating iNSIP from unclassifiable ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for iNSIP - unclassifiable ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>AUC for differentiating iNSIP from unclassifiable ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy for IPAF - CTD-ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>Accuracy for differentiating IPAF from CTD-ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for IPAF - CTD-ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>AUC for differentiating IPAF from CTD-ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy for IPAF - unclassifiable ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>Accuracy for differentiating IPAF from unclassifiable ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for IPAF - unclassifiable ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>AUC for differentiating IPAF from unclassifiable ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy for CTD-ILD - unclassifiable ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>Accuracy for differentiating CTD-ILD from unclassifiable ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC for CTD-ILD - unclassifiable ILD</measure>
    <time_frame>Baseline</time_frame>
    <description>AUC for differentiating CTD-ILD from unclassifiable ILD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease progression</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>FVC decline in combination with worsening of respiratory symptoms (cough and/or dyspnea) and/or progressive fibrosis on CT scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease progression</measure>
    <time_frame>24 months after inclusion</time_frame>
    <description>FVC decline in combination with worsening of respiratory symptoms (cough and/or dyspnea) and/or progressive fibrosis on CT scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy of disease progression</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Relating disease progression (based on FVC decline, CT scan and/or symptoms) to change in eNose values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy of disease progression</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>Relating disease progression (based on FVC decline, CT scan and/or symptoms) to change in eNose values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diagnostic accuracy of disease progression</measure>
    <time_frame>24 months after inclusion</time_frame>
    <description>Relating disease progression (based on FVC decline, CT scan and/or symptoms) to change in eNose values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Worsening of respiratory symptoms (cough and/or dyspnea)</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>Worsening of respiratory symptoms (cough and/or dyspnea) measured on a visual analogue scale (0-10, 0 no symptoms, 10 most severe symptoms)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>Deceased subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality</measure>
    <time_frame>24 months after inclusion</time_frame>
    <description>Deceased subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapeutic effect</measure>
    <time_frame>6 months after start therapy</time_frame>
    <description>Relating start of anti-fibrotic medication to change in eNose values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Therapeutic effect</measure>
    <time_frame>12 months after start therapy</time_frame>
    <description>Relating start of anti-fibrotic medication to change in eNose values</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>L-PF evaluation</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Relating Longitudinal changes in score of L-PF questionnaire to eNose values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>L-PF evaluation</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Relating Longitudinal changes in score of L-PF questionnaire to lung function values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>L-PF evaluation</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>Relating Longitudinal changes in score of L-PF questionnaire to eNose values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>L-PF evaluation</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>Relating Longitudinal changes in score of L-PF questionnaire to lung function values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>L-PF evaluation</measure>
    <time_frame>24 months after inclusion</time_frame>
    <description>Relating Longitudinal changes in score of L-PF questionnaire to eNose values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>L-PF evaluation</measure>
    <time_frame>24 months after inclusion</time_frame>
    <description>Relating Longitudinal changes in score of L-PF questionnaire to lung function values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GRoC evaluation</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Relating Longitudinal changes in score of Global Rating of Change Scale to eNose values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GRoC evaluation</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Relating Longitudinal changes in score of Global Rating of Change Scale to lung function values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GRoC evaluation</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>Relating Longitudinal changes in score of Global Rating of Change Scale to eNose values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GRoC evaluation</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>Relating Longitudinal changes in score of Global Rating of Change Scale to lung function values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GRoC evaluation</measure>
    <time_frame>24 months after inclusion</time_frame>
    <description>Relating Longitudinal changes in score of Global Rating of Change Scale to eNose values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GRoC evaluation</measure>
    <time_frame>24 months after inclusion</time_frame>
    <description>Relating Longitudinal changes in score of Global Rating of Change Scale to lung function values</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>ILD patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients diagnosed with one of the most prevalent fibrotic ILDs: IPF, CHP, CTD-ILD, iNSIP, IPAF, and unclassifiable ILD (defined as unclassifiable disease at the time of the first MDT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Electronic nose</intervention_name>
    <description>First, patients will be asked to rinse their mouth thoroughly with water three times. Subsequently, exhaled breath analysis will be performed in duplicate with a 1-minute interval. An eNose measurement consists of five tidal breaths, followed by an inspiratory capacity maneuver to total lung capacity, a five second breath hold, and subsequently a slow expiration (flow &lt;0.4L/s) to residual volume. The measurements are non-invasive and will cost approximately 5-10 minutes in total, including explanation and informed consent procedure. There are no risks associated with this study and the burden for patients is minimal.</description>
    <arm_group_label>ILD patients</arm_group_label>
    <other_name>SpiroNose</other_name>
    <other_name>eNose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a diagnosis of fibrotic ILD, as discussed in a multidisciplinary team&#xD;
             meeting (50% incident patients and 50% prevalent patients). Patients are classified as&#xD;
             'incident' if they received a diagnosed in a multidisciplinary team meeting within the&#xD;
             past six months. Patients will be required to have fibrosis on a HRCT scan &lt;1 year&#xD;
             before enrollment in the study defined as reticular abnormality with traction&#xD;
             bronchiectasis, with or without honeycombing, as determined by a radiologist. No&#xD;
             minimum extent of fibrosis will be required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Alcohol consumption ≤ 12 hours before the measurement&#xD;
&#xD;
          -  Physically not able to perform eNose measurement&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marlies S Wijsenbeek, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marlies S Wijsenbeek, MD PhD</last_name>
    <phone>+31107030323</phone>
    <phone_ext>+31107030323</phone_ext>
    <email>m.wijsenbeek-lourens@erasmusmc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Lyon 1, Louis Pradel hospital, Lyon. FranceService de pneumologie, hôpital Louis Pradel</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vincent Cottin, Prof.</last_name>
      <phone>+33472357652</phone>
      <email>vincent.cottin@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Kreuter, Prof Dr</last_name>
      <phone>062213960</phone>
      <phone_ext>062213960</phone_ext>
      <email>kreuter@uni-heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris G van der Sar, MD</last_name>
      <phone>0031611056352</phone>
      <phone_ext>0031611056352</phone_ext>
      <email>i.g.vandersar@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Marlies S Wijsenbeek, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Philip L Molyneaux</last_name>
      <phone>+442073528121</phone>
      <phone_ext>+442073528121</phone_ext>
      <email>p.molyneaux@imperial.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 11, 2020</study_first_submitted>
  <study_first_submitted_qc>December 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Marlies Wijsenbeek</investigator_full_name>
    <investigator_title>Principal Investigator, MD PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

